Orphan Drug Designation Granted to Nintedanib
Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Today, Boehringer Ingelheim sent out a press release, announcing that, “… the European Commission (EC) and U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD)”.
Joep Welling from Fesca says: “Scleroderma and associated interstitial lung disease have a devastating impact on the patient community, and we welcome this important news that a potential new treatment has received Orphan Drug Designation. It’s a crucial step forward in helping to address an unmet need and represents important progress for patients with this rare disease.”
news & events
Protect your skin
Skin care is very important when you have systemic sclerosis.
Joining forces in spreading awareness
Come with us on a roadtrip along with Scleroderma Framed in order to spread awareness of Scleroderma.
COVID-19 catalogue
Find reliable information on scleroderma & COVID-19, official pages with information and much more.